Company news

Rezolute, Inc. news in 2026

Rezolute, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Rezolute to Participate in Upcoming Investor Conferences

November 2, 2026

Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

October 14, 2026

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

October 5, 2026

Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update

September 24, 2026

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

September 9, 2026

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

June 17, 2026

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

June 3, 2026

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

June 2, 2026

Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

May 12, 2026

Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting

May 1, 2026

Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting

April 21, 2026

Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting

March 23, 2026

Rezolute to Participate in the Citizens Life Sciences Conference

March 3, 2026

Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

February 12, 2026

Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 3, 2026

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

January 6, 2026

Decks in 2026